Genmab — Juni 2013
-
genmab
-
gsk kommer med salgstal ifm kvartalsregnskab
-
Lidt interessant at han siger, at det allerede nu ændrer praksis, at man bør tage et CD20 antistof i kombination med chlorambucil. Det er selvfølgelig konkurrenten, men måske allerede vi så småt vil begynde at se off label salg for Arzerra i first line - lidt har jo også ret
-
-
spændende
-
-
Dr. Janine Schuurman, Director Strategic Research at Genmab, will give a presentation on the efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange at the International Conference on monoclonal antibodies and cancer stem cells that will be held from 24th to the 26th June 2013
-
The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough
Dr. Richard Pazdur Maybe more than any other person alive, Richard Pazdur, the director of the Food and Drug Administration's Office of Oncology and Hematology Products, personifies the tension between the need to get new drugs to patients fast and the competing desire to make sure they are safe and effective [...]
Forbes (www.forbes.com)
-
tak for den artikel solsen - jeg bed mærke i, at Pazdur specifikt nævnte Hazard Ratio som del af grunden til at afvise...
-
Der bliver kamp til stregen på cd38 antistof markedet: http://www.reuters.com/article/2013/06/26/nj-morphosys-idUSnBw266538a+100+BSW20130626
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind